The Q1 results are in line with expectations for a clinical-stage biotech advancing toward Phase 3. The key catalyst to watch is FDA alignment on the global pivotal program design and the subsequent Phase 3 initiation in late 2026. The April 2026 offering provides a strong cash runway through late 2027, reducing near-term financing risk. Monitor for any FDA feedback that could alter the trial design or timeline.
Price Chart
Executive Summary
GH Research PLC reported Q1 2026 financial results showing a net loss of $19.0 million ($0.31 per share), compared to a $10.8 million loss ($0.19 per share) in Q1 2025, driven by increased R&D spending on GH001 clinical development. The company completed enrolment in two Phase 1 trials and selected doses for the global Phase 3 pivotal program, targeting initiation in late 2026. Cash position was $267.3 million at quarter-end, supplemented by $111.2 million in net proceeds from an April 2026 follow-on offering, extending the cash runway into late 2027.
Key Facts
- Net loss of $19.0 million for Q1 2026 vs $10.8 million in Q1 2025
- Basic and diluted loss per share of $0.31 vs $0.19 in prior year period
- Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026
- Received estimated net proceeds of $111.2 million from April 2026 underwritten offering
- R&D expenses increased 57.6% to $12.4 million from $7.9 million, driven by GH001 clinical and technical development
- Phase 2b results published in JAMA Psychiatry in March 2026
- Completed enrolment in GH001-HV-106 (UK aerosol device study) and GH001-HV-109 (US IND-opening study)
- Doses selected for global Phase 3 pivotal program; targeting initiation in late 2026
- Seeking FDA alignment on Phase 3 program design intended to replicate Phase 2b
- No revenue generated; company remains pre-commercialization
Financial Impact
Net loss widened by $8.2 million YoY to $19.0 million; cash burn from operations was $10.7 million in Q1 2026; post-quarter cash position strengthened to ~$378.5 million including April offering proceeds
Risk Factors
- Phase 3 trial failure or regulatory delays could significantly impair stock value
- Dilution from April 2026 offering (~10.5% increase in shares outstanding) creates overhang
- No revenue expected for several years; dependent on equity markets for future funding
- Competitive landscape includes Spravato (J&J), COMP360 (Compass Pathways), and other psychedelic candidates
- Foreign exchange volatility impacted results by $2.3 million in Q1 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-021153 |
| Document: ef20070494_ex99-2.htm | 0001140361-26-021153 |
| Document: ef20070494_ex99-3.htm | 0001140361-26-021153 |
| Document: ef20070494_6k.htm | 0001140361-26-021153 |
| Document: ef20070494_ex99-4.htm | 0001140361-26-021153 |
| Document: 0001140361-26-021153-index-headers.html | 0001140361-26-021153 |
| Document: 0001140361-26-021153-index.html | 0001140361-26-021153 |
| Document: 0001140361-26-021153.txt | 0001140361-26-021153 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers